ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,078.34
-0.17%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) Noticias

CTMX CytomX Therapeutics Inc

1.3808
-0.0792 (-5.42%)
14 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
CytomX Therapeutics Inc CTMX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.0792 -5.42% 1.3808 23:00:04
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.45 1.375 1.485 1.38 1.46
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/6/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202415:05GLOBECytomX Therapeutics to Present at the Jefferies Global..
17/5/202416:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202416:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202416:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202416:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202416:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:01EDGAR2Form 8-K - Current report
16/5/202415:15GLOBECytomX Therapeutics Announces New Employment Inducement..
13/5/202415:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/5/202415:41EDGAR2Form 8-K - Current report
08/5/202415:10GLOBECytomX Therapeutics Reports First Quarter 2024 Financial..
08/5/202415:04EDGAR2Form 8-K - Current report
08/5/202415:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202415:15GLOBECytomX Therapeutics Announces Clinical Collaboration with..
01/5/202407:00GLOBECytomX Therapeutics to Report First Quarter 2024 Results and..
08/4/202407:00GLOBECytomX Therapeutics Announces First Patient Dosed with..
03/4/202407:00GLOBECytomX Therapeutics Announces Nomination of Second Clinical..
21/3/202407:00GLOBECytomX Therapeutics Appoints Dr. Zhen Su to Board of..
18/3/202407:00GLOBECytomX Therapeutics Announces Milestone Achievement in..
11/3/202415:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202415:10GLOBECytomX Therapeutics Reports 2023 Financial Results and..
11/3/202415:02EDGAR2Form 8-K - Current report
11/3/202415:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202405:39IHMARKETNEWSU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s..
04/3/202407:00GLOBECytomX Therapeutics to Report Fourth Quarter and Full Year..
27/2/202407:00GLOBECytomX Therapeutics to Present at Upcoming March Investor..
24/1/202407:00GLOBECytomX Therapeutics Announces FDA Clearance of IND..
19/1/202419:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202419:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202419:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202419:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202419:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202407:00GLOBECytomX Therapeutics to Present at the B. Riley Securities..
04/1/202407:00GLOBECytomX Therapeutics Outlines 2024 Company Priorities and..
22/12/202315:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202315:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202315:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202307:00GLOBECytomX Therapeutics to Present at the 42nd Annual J.P...
19/12/202318:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202318:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202318:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202318:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202315:15GLOBECytomX Therapeutics Reports Third Quarter 2023 Financial..
07/11/202315:05EDGAR2Form 8-K - Current report
07/11/202315:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202307:00GLOBECytomX Therapeutics to Present at Upcoming November Investor..
31/10/202307:00GLOBECytomX Therapeutics to Report Third Quarter 2023 Financial..
30/10/202307:00GLOBECytomX Therapeutics to Present Preclinical Data for..

Su Consulta Reciente

NASDAQ
CTMX
CytomX Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados